Loading...
XNASCDXS
Market cap396mUSD
Jan 15, Last price  
4.87USD
1D
7.51%
1Q
44.51%
Jan 2017
5.87%
IPO
-65.31%
Name

Codexis Inc

Chart & Performance

D1W1MN
XNAS:CDXS chart
P/E
—
P/S
5.65
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
5.47%
Rev. gr., 5y
2.97%
Revenues
70m
-49.39%
12,127,00025,333,00050,478,00082,908,000107,104,000123,865,00088,298,00031,922,00035,307,00041,804,00048,837,00050,024,00060,594,00068,458,00069,056,000104,754,000138,590,00070,143,000
Net income
-76m
L+126.96%
-18,671,000-38,977,000-45,127,000-20,289,000-8,541,000-16,550,000-30,857,000-41,303,000-19,071,000-7,581,000-8,558,000-22,996,000-10,878,000-11,935,000-24,010,000-21,279,000-33,592,000-76,240,000
CFO
-53m
L
-13,287,000-6,470,000-36,316,000-8,686,000-16,383,000-490,000-11,892,000-22,998,000321,000-433,000-2,701,000-8,763,000-14,094,000-12,560,000-16,464,000-14,267,00011,284,000-52,638,000
Earnings
Feb 26, 2025

Profile

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
URL
https://www.codexis.com/
IPO date
Apr 22, 2010
Employees
248
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
70,143
-49.39%
138,590
32.30%
Cost of revenue
124,944
170,304
Unusual Expense (Income)
NOPBT
(54,801)
(31,714)
NOPBT Margin
Operating Taxes
69
276
Tax Rate
NOPAT
(54,870)
(31,990)
Net income
(76,240)
126.96%
(33,592)
57.86%
Dividends
Dividend yield
Proceeds from repurchase of equity
8,652
(533)
BB yield
-4.16%
0.18%
Debt
Debt current
(2,730)
5,360
Long-term debt
28,267
81,916
Deferred revenue
640
16,881
Other long-term liabilities
1,233
1,371
Net debt
(49,279)
(47,218)
Cash flow
Cash from operating activities
(52,638)
11,284
CAPEX
(4,418)
(8,307)
Cash from investing activities
(4,858)
(13,578)
Cash from financing activities
8,167
(575)
FCF
(16,934)
(17,280)
Balance
Cash
65,116
113,984
Long term investments
9,700
20,510
Excess cash
71,309
127,564
Stockholders' equity
(497,523)
(421,284)
Invested Capital
602,035
627,971
ROIC
ROCE
EV
Common stock shares outstanding
68,131
65,344
Price
3.05
-34.55%
4.66
-85.10%
Market cap
207,800
-31.76%
304,503
-84.92%
EV
158,521
257,285
EBITDA
(44,878)
(21,463)
EV/EBITDA
Interest
1,441
Interest/NOPBT